嵌合抗原受体 T 细胞疗法后急性淋巴细胞白血病前葡萄膜浸润症状缓解

IF 0.5 Q4 OPHTHALMOLOGY Journal of VitreoRetinal Diseases Pub Date : 2024-08-31 DOI:10.1177/24741264241275247
Jaskirat S Takhar, Ankur A Mehra, Shree K Kurup, Warren M Sobol, Rabail Aslam, Kwadwo A Oduro, Jose J Echegaray
{"title":"嵌合抗原受体 T 细胞疗法后急性淋巴细胞白血病前葡萄膜浸润症状缓解","authors":"Jaskirat S Takhar, Ankur A Mehra, Shree K Kurup, Warren M Sobol, Rabail Aslam, Kwadwo A Oduro, Jose J Echegaray","doi":"10.1177/24741264241275247","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> To present a case of acute B-cell lymphoblastic leukemia (B-ALL) ocular relapse treated with chimeric antigen receptor T-cell (CAR T) therapy. <b>Methods:</b> A retrospective case review was evaluated. <b>Results:</b> A 69-year-old woman with a history of B<b>-</b>ALL presented with bilateral hypopyons and 3+ anterior chamber cells that responded to topical prednisolone. Six months later, she developed recurrent hypopyons, iris neovascularization, and iris nodularity in both eyes. A fine-needle aspiration biopsy confirmed ocular infiltration of B-ALL. A single infusion of CAR T therapy resulted in remission of the systemic and ocular findings. The clinical course was complicated by cytokine release syndrome and neurotoxicity, which improved with medical management. The patient remained in remission for 7 months after a single CAR T infusion. <b>Conclusions:</b> CAR T therapy may be effective in treating systemic leukemia and uveal infiltration, with an ocular side-effect profile and visual outcomes. The systemic side effects of CAR T therapy may be managed medically.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264241275247"},"PeriodicalIF":0.5000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562240/pdf/","citationCount":"0","resultStr":"{\"title\":\"Resolution of Anterior Uveal Infiltration of Acute Lymphoblastic Leukemia After Chimeric Antigen Receptor T-Cell Therapy.\",\"authors\":\"Jaskirat S Takhar, Ankur A Mehra, Shree K Kurup, Warren M Sobol, Rabail Aslam, Kwadwo A Oduro, Jose J Echegaray\",\"doi\":\"10.1177/24741264241275247\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Purpose:</b> To present a case of acute B-cell lymphoblastic leukemia (B-ALL) ocular relapse treated with chimeric antigen receptor T-cell (CAR T) therapy. <b>Methods:</b> A retrospective case review was evaluated. <b>Results:</b> A 69-year-old woman with a history of B<b>-</b>ALL presented with bilateral hypopyons and 3+ anterior chamber cells that responded to topical prednisolone. Six months later, she developed recurrent hypopyons, iris neovascularization, and iris nodularity in both eyes. A fine-needle aspiration biopsy confirmed ocular infiltration of B-ALL. A single infusion of CAR T therapy resulted in remission of the systemic and ocular findings. The clinical course was complicated by cytokine release syndrome and neurotoxicity, which improved with medical management. The patient remained in remission for 7 months after a single CAR T infusion. <b>Conclusions:</b> CAR T therapy may be effective in treating systemic leukemia and uveal infiltration, with an ocular side-effect profile and visual outcomes. The systemic side effects of CAR T therapy may be managed medically.</p>\",\"PeriodicalId\":17919,\"journal\":{\"name\":\"Journal of VitreoRetinal Diseases\",\"volume\":\" \",\"pages\":\"24741264241275247\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2024-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562240/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of VitreoRetinal Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/24741264241275247\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of VitreoRetinal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/24741264241275247","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:介绍一例采用嵌合抗原受体 T 细胞(CAR T)疗法治疗的急性 B 细胞淋巴细胞白血病(B-ALL)眼部复发病例。研究方法对病例进行回顾性评估。结果一名 69 岁的女性患者曾患 B-ALL 病史,出现双侧眼睑下垂和 3+ 前房细胞,对局部强的松龙治疗有反应。6 个月后,她的双眼反复出现视力减退、虹膜新生血管和虹膜结节。细针穿刺活检证实了 B-ALL 的眼部浸润。单次输注 CAR T 疗法后,全身和眼部症状均得到缓解。临床过程因细胞因子释放综合征和神经毒性而变得复杂,但经过药物治疗后情况有所改善。单次输注 CAR T 治疗后,患者病情持续缓解了 7 个月。结论CAR T疗法可有效治疗全身性白血病和葡萄膜浸润,同时具有眼部副作用和视觉效果。CAR T疗法的全身副作用可通过药物控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Resolution of Anterior Uveal Infiltration of Acute Lymphoblastic Leukemia After Chimeric Antigen Receptor T-Cell Therapy.

Purpose: To present a case of acute B-cell lymphoblastic leukemia (B-ALL) ocular relapse treated with chimeric antigen receptor T-cell (CAR T) therapy. Methods: A retrospective case review was evaluated. Results: A 69-year-old woman with a history of B-ALL presented with bilateral hypopyons and 3+ anterior chamber cells that responded to topical prednisolone. Six months later, she developed recurrent hypopyons, iris neovascularization, and iris nodularity in both eyes. A fine-needle aspiration biopsy confirmed ocular infiltration of B-ALL. A single infusion of CAR T therapy resulted in remission of the systemic and ocular findings. The clinical course was complicated by cytokine release syndrome and neurotoxicity, which improved with medical management. The patient remained in remission for 7 months after a single CAR T infusion. Conclusions: CAR T therapy may be effective in treating systemic leukemia and uveal infiltration, with an ocular side-effect profile and visual outcomes. The systemic side effects of CAR T therapy may be managed medically.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.20
自引率
16.70%
发文量
0
期刊最新文献
Clinical Profiles of Retinal Vasoproliferative Tumors. Serpiginous Choroiditis After COVID-19 Infection. Ischemic Retinopathy Associated With Mantle Cell Lymphoma-Induced Vascular Occlusion. Antivascular Endothelial Growth Factor Injections for the Chronic Treatment of Macula-off, Fovea-on Diabetic Tractional Retinal Detachment With Vitreous Hemorrhage. Exudative Vitreoretinopathy With a Coats-Like Response in Poretti-Boltshauser Syndrome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1